Injectsense announces first human implant of ultraminiature IOP sensor

News
Article

Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.

IOP detecting sensor and its applicator Image credit: Injectsense

Image credit: Injectsense

Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.1 The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.

"From a physician's perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment," said Mura in the release. "It's extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7."

Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.1

"Although safety is the primary focus of this study, we are also informing our product design to meet the expectations of ophthalmologists across the globe," said Ariel Cao, President/CEO of Injectsense. "We expect these sensors to be easily delivered in the doctor's office."

In November 2023, Injectsense announced that it secured $9.4 million in funding with sister company Injectpower to bring the implantable device into production.2

References:
  1. Injectsense completes first human implantation of its ultraminiaturized intraocular pressure sensor. PR Newswire. News release. August 27, 2024. Accessed August 28, 2024. https://www.prnewswire.com/news-releases/injectsense-completes-first-human-implantation-of-its-ultraminiaturized-intraocular-pressure-sensor-302231827.html
  2. Injectsense and solid-state microbattery partner Injectpower secure $9.4 million for implantable device supply chain and support of clinical studies. Injectsense. News release. November 15, 2023. Accessed August 28, 2024. https://www.injectsense.com/1-7m-sbir-grant
Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.